BBNX SCHEDULE 13G/A: SEC filing
Soleus Capital entities
Filed with the SEC on · accession 0001213900-26-117545
BBNX filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 9, 2026. A report the company filed with the SEC (the US market regulator).
Summary of the filing
Soleus Capital entities filed an amended Schedule 13G reporting beneficial ownership of Beta Bionics common stock, with Soleus Capital Master Fund holding 3,783,237 shares (6.8%) and Soleus Private Equity Fund II holding 1,003,961 shares (1.8%).
Key details
✦ Ask GOAX AI about this filing — what it means for BBNX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for BBNX?
Click hereFrequently asked questions
What did BBNX file with the SEC on Nov 9, 2026?
BBNX filed a SCHEDULE 13G/A (SEC filing). Soleus Capital entities filed an amended Schedule 13G reporting beneficial ownership of Beta Bionics common stock, with Soleus Capital Master Fund holding 3,783,237 shares (6.8%) and Soleus Private Equity Fund II holding 1,003,961 shares (1.8%).
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
Other BBNX SEC filings
- 10-Q · SEC filingOct 27, 2026
- 8-K · Guidance raiseOct 27, 2026
- SCHEDULE 13G · SEC filingOct 7, 2026
- 8-K · Secondary offeringSep 17, 2026
- 424B5 · Secondary offeringSep 17, 2026
- 424B5 · Secondary offeringSep 16, 2026
- 8-K · Fda approvalSep 15, 2026
- SCHEDULE 13G/A · SEC filingAug 13, 2026
- 10-Q · SEC filingJul 29, 2026
- 8-K · Guidance raiseJul 29, 2026
Get alerts when BBNX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days